CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers
This study has been completed.
Information provided by (Responsible Party):
First received: February 23, 2012
Last updated: October 1, 2012
Last verified: October 2012
This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.
Duchenne Muscular Dystrophy
Becker Muscular Dystrophy
|Official Title:||An Open-label, Un-controlled, Single-centre Trial Investigating the Efficacy and Safety of CRD007 in Children With Duchenne Muscular Dystrophy (DMD) or Becker Muscular Dystrophy (BMD) or Children Being Symptomatic Carriers for DMD or BMD|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Cardoz AB:
Contacts and Locations